Toggle Main Menu Toggle Search

Open Access padlockePrints


Lookup NU author(s): Professor Sir John BurnORCiD, Professor Patrick Chinnery


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Neuroferritinopathy (MIM 606159, also labeled hereditary ferritinopathy and neurodegeneration with brain iron accumulation type 2, NBIA2) is an adult-onset progressive movement disorder caused by mutations in the ferritin light chain gene (FTL1). Four pathogenic mutations in FTL1 have been described to date; 460insA was our original founder mutation in Cumbria, North West England, where it arose before 1800. The same mutation appears to have arisen separately in France. The resulting altered reading frame extends the peptide, disrupting the ferritin dodecahedron structure and causing accumulation of ferritin and iron, primarily in central neurons. A wide range of neurologic symptoms may occur; 50% present with chorea, 43% with limb dystonia, and 7% with Parkinsonian features. The disorder provides a direct link between disordered iron storage and a neurodegenerative disease, opening new avenues for treatment by altering brain iron stores in addition to symptomatic treatments such as local Botulinum toxin and oral anti oxidants. © 2006 Elsevier Inc. All rights reserved.

Publication metadata

Author(s): Burn J, Chinnery PF

Publication type: Review

Publication status: Published

Journal: Seminars in Pediatric Neurology

Year: 2006

Volume: 13

Issue: 3

Pages: 176-181

ISSN (print): 1071-9091

ISSN (electronic): 1558-0776


DOI: 10.1016/j.spen.2006.08.006

PubMed id: 17101456